Juno Therapeutics: Corporate Presentation (Juno Therapeutics) - Sep 27, 2015 - Anticipated P1/2 data in adult AML by early 2016; Anticipated P1 data in adult NSCLC by early 2016
Anticipated P1 data • Anticipated P1/2 data • Non Small Cell Lung Cancer • Oncology
|